Biomedical subjects

Gilbert Pochmalicki

Publications and source records attributed to Gilbert Pochmalicki.

4 recordsLinked to original sources

PubMed2004

[Changes in the management of cardiac arrest].

NEW RECOMMENDATIONS: for cardio-pulmonary resuscitation Methods such as mouth to mouth or the search for a pulse, until now the fundamental preliminaries, have now become second line. Everything must be organised to allow for defibrillation as rapidly as possible. NEW MODALITIES FOR CARDIAC MASSAGE: The frequency of compressions recommended is currently 100 per minute in the adult with a rhythm of compression-ventilation reaching 15/2 before intubation. Concerning the haemodynamic agents for cardiac arrest, the efficacy of high doses of adrenalin is not greater than with conventional doses. Vasopressin is not superior to intravenous adrenalin regarding survival at 24 hrs exepet in case of asystoly. Dopamine at a "renal" dose is no longer used. ANTIARRYTHMICS: Amiodarone is part of the decisional tree in the case of ventricular fibrillation or ventricular tachycardia without a pulse. Semi-automatic defibrillator accessibility should be generalized. INFUSED SOLUTIONS: Sodium bicarbonate does not improve the survival except in particular cases. Physiological serum should be preferred to glucosed serum during reanimation.

Adult↗

PubMed2004

[Acute coronary syndromes without ST segment elevation].

NEW DENOMINATIONS: With the arrival of new therapeutic strategies requiring rapid intervention, acute coronary syndromes required classification on earlier data than the Q-wave or MB creatinine kinase. In a patient with anginal pain and depending on the electrocardiogram, we now distinguish syndromes with or without ST segment elevation. REGARDING ANTIPLATELET DRUGS: Aspirin is used in all cases, as well as clopidogrel. Anti PG IIb-IIIa agents are set aside only for the forms at risk, when an angioplasty is envisaged in the short term. ANTICOAGULANTS: Enoxaparin has demonstrated its superiority over unfractionated heparin. In general, the biological controls are not indispensables; they can however be used in certain cases (notably elderly patients). OTHER TREATMENTS: These are beta-blockers (first dose via the intravenous route in the case of persisting pain, then relay to the oral route), calcium-channel blockers (diltiazem, verapamil) when beta-blockers are contraindicated, nitrate derivatives with demonstrated antalgic effect but not to be used if an extension to the right ventricle or low blood pressure is suspected, nasal oxygen in the case of cyanosis or respiratory distress, enzyme conversion inhibitors if hypertension persists, and repeated intravenous injections of morphine in the case of persisting intense pain. CORONARY REVASCULARISATION: In all the patients considered at high risk, coronary revascularisation is recommended within the first 24 hours, when technically possible.

Acute Disease↗

PubMed2004

[Acute coronary syndromes with ST-segment elevation].

UNBLOCK THE CORONARY ARTERIES: For the treatment of acute coronary syndromes with ST-segment elevation, emergency repermeabilisation is of the artery is crucial, generally by primary angioplasty than by fibrinolysis. The other treatments have little beneficial effects on mortality. Primary angioplasty is the technique of choice when it can be performed in the intensive care units with staff with sufficient experience and within the 90 minutes following the preliminary medical management, and benefiting from the supply of PG IIb-IIIa. THROMBOLYSIS: Performed before the twelfth hour, thrombolysis reduces mortality. The earlier it is performed the greater the benefits. A significant reduction is mortality is observed even in patients aged over 75. The indications for coronography are determined by the existence of clinical risk factors and by the data of supplementary non-invasive examinations (sonography, scintigraphy, effort testing). When clinical risk factors exist from the start, a coronography must be performed. In the absence of initial risks, and if the non-invasive examination reveals risk factors, then a coronarography should be performed.

Adrenergic beta-Antagonists↗

PubMed2004

[Diagnostic and therapeutic progress. Venous thromboembolism, cardiac insufficiency and radio contrast agents].

MODALITIES FOR THE DIAGNOSIS OF VENOUS THROMBOEMBOLISM: Currently rely on the confrontation of the initial clinical data and the results of D-dimer measurements, a venous Doppler, although reliable, is not a first-line exploration. REGARDING TREATMENT: Indications for thrombolysis are currently limited to massive pulmonary oedema with shock. Alteplase added to heparin improves the progression of severe embolism; it spares the patients from heavy interventions of resuscitation but the mortality remains the same. Concerning anticoagulant treatments, prolonged antivitamin K at classical doses is more effective than low doses and for limited duration if phlebitis is an idiopathic one. FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION: Treatment of these heart failures, formerly know as 'diastolic' is similar to that of the acute phase of systolic heart failure. However, care should be taken with vasodilatators. CONCERNING HEART FAILURE IN GENERAL: The brain natriuretic peptide (BNP) represents a remarkable progress for the aetiological diagnosis of dyspnoea (inferior to 80 pg/ml in the case of pulmonary origin, superior to 300 pg/ml in the case of cardiac origin or severe pulmonary embolism). Regarding treatment, for acute heart failure, it is still the association of nitrates and diuretics, with oxygen therapy and eventually inotropics. Beta-blockers, which have revolutionized the treatment of chronic heart failure, must be maintained whenever possible in the case of the onset of acute pulmonary oedema. Multisite pacing is increasingly used in refractory chronic heart failure. Implantable defibrillation has become common practice. Non-invasive ventilation (Bi or C-PAP) is interesting in acute cardiogenic pulmonary oedema. THE PREVENTIVE ROLE OF N ACETYL-CYSTEINE: N acetyl cysteine reduces the incidence of nephropathies induced by the radio contrast products in patients with chronic kidney failure. Combined with hydratation, it must be proposed the day before and on the day of the procedure in any patient with diabetes or kidney failure.

Acetylcysteine↗